Register Now: Does Your Pharmaceutical WMS Grow with You?
News|Articles|March 4, 2025

Pharma Pulse 3/4/25: How to Mitigate a Potential Drop in Demand Due to Tariffs, What ‘Going Wild’ on Healthcare Could Mean & more

The latest news for pharma industry insiders.

How Pharmaceutical Companies Can Mitigate a Potential Drop in Demand Due to Tariffs

In this part of his Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, identifies strategies that pharmaceutical companies and digital health platforms can employ to navigate a potential drop in demand due to tariff-induced increased costs.

What ‘Going Wild’ on Healthcare Could Mean: The Early Days of Trump Healthcare

Three Washington, D.C., healthcare policy experts and the former chief of staff of HHS dive into the healthcare politics and policies of the new administration: RFK Jr.’s confirmation hearings; the future of IRA drug price negotiations and PBM reform; Medicare Advantage under the new administration; DOGE cuts at HHS; and ant-DEI and the social determinants of health.

AbbVie Enters Obesity Market With Up to $2.2 Billion Gubra Deal

AbbVie Inc. agreed to pay as much as $2.2 billion for a next-generation obesity drug from Danish biotech Gubra A/S, marking its entry into the hyper-competitive weight-loss market.

Tenovi and GenieMD Forge Transformative Partnership to Expand Access to Remote Care and Enhance Medication Adherence

GenieMD and Tenovi have joined forces to enhance access to care through transformative virtual care models. The collaboration debuts with the Tenovi Pillbox, empowering individuals managing chronic conditions and their caregivers with real-time medication adherence tracking from home.

Nicholas Saraceno on LinkedIn

🗞️ The latest development in the tariff news - after an initial 30-day pause, President Trump plans to re-enact the import taxes on the nation’s trading partners—while also doubling the 10% tariff on China.

You can find continuous updates of the situation, along with the latest news and insights, via Pharmaceutical Commerce Magazine. ⬇️

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs


Related to this article

CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.